Flagship and portfolio companies do deals with GSK, Merck KGaA and Saudi Arabianews2025-11-20T14:27:08+00:00November 20th, 2025|Endpoints News|
Aspen gets $115M for Parkinson’s cell therapy, potential IPO in sight next yearnews2025-11-20T12:02:48+00:00November 20th, 2025|Endpoints News|
Ensoma halves workforce as genetic medicines startup enters clinicnews2025-11-19T20:52:55+00:00November 19th, 2025|Endpoints News|
SixPeaks CEO talks about $170M sale to AstraZeneca and what comes next in obesitynews2025-11-18T15:47:23+00:00November 18th, 2025|Endpoints News|
J&J to buy Halda for $3.05B, adding startup’s RIPTAC cancer drugnews2025-11-17T14:27:30+00:00November 17th, 2025|Endpoints News|
Solve Therapeutics rakes in $120M for two mystery ADCsnews2025-11-17T13:03:19+00:00November 17th, 2025|Endpoints News|
Ex-Lilly Diabetes leaders hunt for new obesity drugs at VC firmnews2025-11-10T14:00:26+00:00November 10th, 2025|Endpoints News|
Eccogene targets $150M in HKEX listing for MASH, obesity drugsnews2025-11-07T11:30:06+00:00November 7th, 2025|Endpoints News|
Zuckerberg-backed Biohub hires EvolutionaryScale team in apparent end of AI startupnews2025-11-07T00:06:20+00:00November 7th, 2025|Endpoints News|
Research institute FutureHouse debuts AI scientist Kosmos and for-profit spinoffnews2025-11-05T12:00:33+00:00November 5th, 2025|Endpoints News|
